Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Dubsky

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
Breast (Edinburgh, Scotland)|July 15, 2014
Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patientsAnna S Berghoff, Rupert Bartsch, Matthias Preusser, et al.
Clinical Breast Cancer|July 22, 2015
Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel ChemotherapyRegina Promberger, Peter Dubsky, Martina Mittlböck, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2014
BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapyMathilde Foedermayr, Miriam Sebesta, Margaretha Rudas, et al.
Breast Cancer Research and Treatment|May 2, 2019
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy aloneIvana Sestak, Miguel Martín, Peter Dubsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2019
Prediction of Distant Recurrence Using EndoPredict Among Women with ER<sup>+</sup>, HER2<sup>-</sup> Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy OnlyMartin Filipits, Peter Dubsky, Margaretha Rudas, et al.
Investigative Radiology|October 26, 2018
Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer PatientsAmirhessam Tahmassebi, Georg J Wengert, Thomas H Helbich, et al.
Breast Care (Basel, Switzerland)|December 17, 2010
Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect RatioPeter Blaha, Ruth Exner, Andrea Dal Borgo, et al.
BMC Cancer|October 20, 2009
Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancerRupert Bartsch, Catharina De Vries, Ursula Pluschnig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2011
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancerZsuzsanna Bago-Horvath, Margaretha Rudas, Peter Dubsky, et al.
Pharmacoeconomics|November 19, 2014
Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patientsPatricia R Blank, Martin Filipits, Peter Dubsky, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
Breast (Edinburgh, Scotland)|July 15, 2014
Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patientsAnna S Berghoff, Rupert Bartsch, Matthias Preusser, et al.
Clinical Breast Cancer|July 22, 2015
Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel ChemotherapyRegina Promberger, Peter Dubsky, Martina Mittlböck, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2014
BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapyMathilde Foedermayr, Miriam Sebesta, Margaretha Rudas, et al.
Breast Cancer Research and Treatment|May 2, 2019
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy aloneIvana Sestak, Miguel Martín, Peter Dubsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2019
Prediction of Distant Recurrence Using EndoPredict Among Women with ER<sup>+</sup>, HER2<sup>-</sup> Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy OnlyMartin Filipits, Peter Dubsky, Margaretha Rudas, et al.
Investigative Radiology|October 26, 2018
Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer PatientsAmirhessam Tahmassebi, Georg J Wengert, Thomas H Helbich, et al.
Breast Care (Basel, Switzerland)|December 17, 2010
Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect RatioPeter Blaha, Ruth Exner, Andrea Dal Borgo, et al.
BMC Cancer|October 20, 2009
Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancerRupert Bartsch, Catharina De Vries, Ursula Pluschnig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2011
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancerZsuzsanna Bago-Horvath, Margaretha Rudas, Peter Dubsky, et al.
Pharmacoeconomics|November 19, 2014
Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patientsPatricia R Blank, Martin Filipits, Peter Dubsky, et al.
Pageof 10